Key Points
- Kush Parmar, a director of Entrada Therapeutics, sold 200,000 shares on November 14 at an average price of $8.80 for proceeds of $1.76 million, cutting his stake by 6.32% to 2,963,066 shares as disclosed in an SEC filing.
- Entrada (NASDAQ:TRDA) recently reported quarterly EPS of - $1.06 (missing estimates) with $1.61M revenue and negative margins, the stock trades around $8.82 with a one-year range of $4.93–$21.79, and analysts have a consensus rating of "Moderate Buy" with a $20.67 price target.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Kush Parmar sold 200,000 shares of Entrada Therapeutics stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $8.80, for a total value of $1,760,000.00. Following the sale, the director directly owned 2,963,066 shares of the company's stock, valued at $26,074,980.80. This trade represents a 6.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Entrada Therapeutics Stock Performance
TRDA opened at $8.82 on Wednesday. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $21.79. The company has a market cap of $337.10 million, a P/E ratio of -3.54 and a beta of -0.08. The business's 50-day simple moving average is $6.38 and its 200-day simple moving average is $6.66.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.02). The business had revenue of $1.61 million during the quarter, compared to analyst estimates of $8.62 million. Entrada Therapeutics had a negative net margin of 168.16% and a negative return on equity of 26.42%. As a group, analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Entrada Therapeutics
Hedge funds have recently made changes to their positions in the business. Massachusetts Financial Services Co. MA grew its holdings in shares of Entrada Therapeutics by 28.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 86,310 shares of the company's stock worth $780,000 after buying an additional 18,926 shares during the last quarter. Mackenzie Financial Corp lifted its position in Entrada Therapeutics by 26.9% during the 1st quarter. Mackenzie Financial Corp now owns 18,396 shares of the company's stock worth $166,000 after acquiring an additional 3,896 shares during the period. Invesco Ltd. grew its stake in shares of Entrada Therapeutics by 45.1% in the 1st quarter. Invesco Ltd. now owns 16,691 shares of the company's stock valued at $151,000 after purchasing an additional 5,187 shares during the last quarter. Nuveen LLC acquired a new position in shares of Entrada Therapeutics in the first quarter valued at approximately $606,000. Finally, American Century Companies Inc. increased its holdings in shares of Entrada Therapeutics by 13.5% in the first quarter. American Century Companies Inc. now owns 67,793 shares of the company's stock valued at $613,000 after purchasing an additional 8,083 shares during the period. Institutional investors and hedge funds own 86.39% of the company's stock.
Analysts Set New Price Targets
TRDA has been the topic of a number of recent analyst reports. Roth Capital set a $13.00 target price on shares of Entrada Therapeutics in a research report on Thursday, November 6th. Zacks Research raised Entrada Therapeutics to a "hold" rating in a report on Friday, August 8th. Weiss Ratings restated a "sell (d-)" rating on shares of Entrada Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.67.
View Our Latest Report on TRDA
Entrada Therapeutics Company Profile
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
